Global Balloon Catheter Market Poised for Robust Growth, Projected to Reach USD 6.4 Billion by 2033

The global balloon catheter market is set to experience substantial growth over the next decade, with a projected compound annual growth rate (CAGR) of 4.3% from 2023 to 2033, according to a new report published today. Currently valued at approximately USD 4.2 billion, the market is expected to soar to USD 6.4 billion by the end of the forecast period, underscoring the vital role of balloon catheters in modern medical procedures.

This growth is driven by ongoing innovation and technological advancements in balloon catheter design, which are essential for performing increasingly complex medical procedures. Industry leaders are at the forefront of developing state-of-the-art technologies that enhance the efficiency, safety, and comfort of medical interventions, thereby revolutionizing interventional cardiology and other fields.

Key factors fueling this market expansion include:

  • Rising Prevalence of Cardiovascular Diseases: As cardiovascular diseases continue to rise globally, the demand for effective and minimally invasive treatment options, such as balloon catheters, is increasing.
  • Aging Population: With a growing geriatric population worldwide, there is a higher demand for procedures that offer less recovery time and reduced surgical risks.
  • Demand for Minimally Invasive Procedures: Patients and healthcare providers alike are prioritizing less invasive treatment options, which has led to a surge in the use of advanced balloon catheters.

Investments in research and development are paving the way for the next generation of balloon catheters, promising better patient outcomes and more efficient healthcare delivery. These advancements are expected to meet the evolving needs of the healthcare sector, providing medical professionals with tools that enhance procedural accuracy and reduce recovery times for patients.

The report also highlights the importance of strategic partnerships and collaborations among key market players. These alliances are essential for accelerating innovation and expanding market reach. By combining resources and expertise, industry leaders can drive further advancements and unlock new growth opportunities within the balloon catheter market.

Industry Outlook:

With a dynamic environment for investment and development, the balloon catheter market is poised for continued growth, offering significant opportunities for stakeholders, including manufacturers, healthcare providers, and investors. As the global healthcare landscape continues to evolve, the demand for advanced, efficient, and safe medical devices like balloon catheters remains stronger than ever.

Key Takeaways from the Balloon Catheter Market:

  • From 2023 to 2033, the United Kingdom market is likely to accelerate at a CAGR of 4.8% and reach a value of USD 273.4 million in 2033.
  • Germany market is also anticipated to expand at 4.7% CAGR and reach USD 244.3 million in 2033.
  • The global balloon catheter market is expected to register 4.3% CAGR between 2023 and 2033.
  • A value of USD 6.4 billion is estimated for the global balloon catheter market in the year 2033.
  • The global balloon catheter market is poised to reach a valuation of USD 4.2 billion in 2023.
  • Rising prevalence of peripheral artery disease (PAD) is slated to fuel the need for balloon catheters in Europe.

“As peripheral artery disease is on rise in Europe, balloon catheter adoption is expected to skyrocket in the coming years. Key players are focusing on developing catheters that improve treatment outcomes.”– Says an FMI Analyst.

Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!

Competition Landscape in the Balloon Catheter Market:

To set themselves apart from their rivals in the industry and boost sales in the global balloon catheter market, manufacturing companies are concentrating on merger and acquisition strategies.

  • Boston Scientific Inc.,
  • Medtronic,
  • Terumo Corporation,
  • B. Braun Melsungen AG,
  • MicroPort Scientific Corporation,
  • Jotech GmbH,
  • QX Medical LLC,
  • Meril Life Pvt. Ltd.,
  • Hexacath,
  • Abbott Laboratories

Recent Developments:

  • In October 2022, Biosense Webster, Inc., a Johnson & Johnson subsidy of medical technologies, revealed its European debut of a HELIOSTAR balloon catheter, the first radiofrequency balloon ablation catheter. It can be utilised for cardiac ablation when coupled with a suitable cross RF generator and catheter-based heart electrophysiological imaging of the atria.
  • In July 2021, PrevailTM drug coated balloon (DCB) catheters were introduced in Europe under the CE (Conformité Européenne) standard by Medtronic plc, a leading company in medical technology. The Prevail DCB is used in percutaneous coronary intervention (PCI) treatments to treat blocked or restricted blood vessels in people with cardiovascular disease.

Key Segments Profiled in the Balloon Catheter Market Survey:

By Product Type:

  • Normal
  • Cutting
  • Scoring
  • Drug Eluting
  • Others

By Raw Material:

  • Polyurethane
  • Nylon
  • Others

By Indication:

  • Coronary Artery Disease
  • Peripheral Vascular Disease

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Women’s Health Supplement Market to Reach USD 2,94,014.8 Million by 2034 expand at a CAGR of 7.5%

As per Future Market Insights’ latest research, the valuation of the global women’s health supplement market was around USD 1,42,645.6 million in 2023, and it is expected to show a CAGR of about 7.5% over the forecast period. The market is expected to reach a valuation of USD 2,94,014.8 million in 2034 from USD 1,52,169.9 million in 2024.

The women’s health supplement market has been expanding in recent years. Women are refocusing on taking vitamins & minerals and practicing preventative medicine.

Around half of women over the age of 65 in North Carolina are said to be dealing with two or more chronic conditions, according to the Center for Women’s Health Research at UNC Report Card 2022. It is a progress report that focuses on the health and healthcare requirements of North Carolina’s 5+ million women. Chronic illness has a detrimental effect on women’s general physical, emotional, and financial well-being.

Women suffering from post-menopausal symptoms of hot flashes, calcium deficiency, difficulty in concentrating, depression, and mental confusion are commonly found problems. Along with this, anemia is extremely common in women of menstruating age, for whom these dietary supplements are very beneficial on a day-to-day basis.

The National Health and Nutrition Examination Survey found that 57.6% of people in the United States aged 20 and above have used a dietary supplement within the previous 30 days. Women were more likely than men to have done so (63.8%).

Due to the rising number of working women and their increased concern for well-being, the demand for different health & beauty supplements has been rising globally. The market for several health supplements among women to keep them fit to deal with a fast-paced life has also been considerably impacted. This is due to the increased awareness among women to maintain a healthy lifestyle and minimize stress.

Key Takeaways from Women’s Health Supplement Market Study

  • The global women’s health supplement industry exhibited a CAGR of around 1% in the historical period from 2019 to 2023.
  • The United States is anticipated to showcase a steady CAGR of around 5% in the forecast period.
  • India’s women’s health supplement industry is anticipated to exhibit a CAGR of around 5% from 2024 to 2034.
  • The women’s beauty supplement market in China is projected to hold a share of around 1% in 2034.
  • Based on type, the vitamins & minerals segment is set to witness a CAGR of 7% from 2024 to 2034.
  • In terms of dosage form, the capsule segment is expected to showcase a CAGR of 0% in the forecast period.

“An increasing number of women are going through menopause and perimenopause as a result of global population aging. Women in developing nations, where health and wellness knowledge may be limited, frequently find menopause symptoms, such as hot flashes and disturbed sleep, to be mysterious. As a result, medical practitioners who travel to rural areas have begun to advise women to take health supplements,” says a lead analyst at Future Market Insights (FMI).

Elevated Market Interest: Delve into In-Depth Trends and Insights with Our Full Report!

Competition Landscape

The women’s health supplement market is witnessing high demand as individuals become increasingly concerned about their health. This has led to a surging adoption of these supplements by customers, driving growth of the market. The market is characterized by the presence of several players, including local, emerging, and established companies.

For instance,

  • In June 2022, Herbalife Nutrition, a renowned global nutrition company, partnered with Village Book Builders to not only promote economic opportunities but also provide education to young people in Ghana and Mexico.
  • In September 2021, Solaray Inc. announced a comprehensive rebranding initiative aimed at directly engaging consumers and inspiring them to embrace meaningful moments in life, regardless of their stage on the wellness journey.

Key Companies Profiled:

Abbott; Vitabiotics Ltd.; Herbalife Nutrition; Natural Health Concept; GNC Holdings; Biocyte Laboratory; Amway; NOW Health; AdvoCare; Nature’s Bounty; Banyan Botanicals; Source Naturals; Nature’s Way Products; Nutramarks Inc.; Natural Immunogenics; Nutramax Laboratories; Solaray Inc.; Sambucol USA; Quantum Health, Inc.; Rainbow Light; Pure Encapsulations, LLC.; Country Life, LLC; INFINITUS; Real Nutriceutical; Southernature

Women’s Health Supplement Market Outlook by Category:

By Type:

  • Vitamins & Minerals
  • Proteins
  • Amino Acids
  • Other Nutritional Substances

By Dosage Form:

  • Tablets
  • Capsules
  • Powders
  • Liquid

By Distribution Channel:

  • Hypermarkets/Supermarkets
  • Specialty Stores
  • Pharmacy & Drug Stores
  • Online Retail

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Interactive Wound Dressing Market Set for Remarkable Growth Projected to Reach USD 9.0 Billion by 2034 exhibit a CAGR of 5.6%

The global interactive wound dressing market is on track for impressive expansion, with forecasts indicating a surge from USD 5.2 billion in 2024 to an astounding USD 9.0 billion by 2034. This anticipated growth reflects a robust Compound Annual Growth Rate (CAGR) of 5.6% over the next decade, highlighting the significant impact of interactive wound dressings in modern healthcare.

Interactive wound dressings are emerging as a transformative force in the medical field, revolutionizing wound care with cutting-edge technology. These advanced dressings are not only improving patient outcomes but also enhancing overall care delivery by offering a more patient-centric approach. By integrating technological innovations, interactive wound dressings provide superior comfort, efficacy, and efficiency, making them a pivotal component of contemporary wound management practices.

“The trajectory of the interactive wound dressing market reflects a paradigm shift in wound care management,” stated FMI. “Technological innovations coupled with a growing emphasis on personalized healthcare have propelled the adoption of interactive dressings, empowering healthcare providers to deliver optimized care experiences while enhancing patient outcomes.”

Key drivers fueling the expansion of the interactive wound dressing market include:

  • Technological Advancements: Continuous innovation in materials science, sensor technology, and advanced wound care solutions are driving the development of interactive dressings with enhanced functionalities, such as real-time monitoring of wound status and targeted therapeutic interventions.
  • Patient-Centric Care: A growing focus on patient-centered care is driving the demand for interactive wound dressings that prioritize patient comfort, convenience, and mobility. These dressings empower patients to actively participate in their healing journey while minimizing discomfort and promoting faster recovery.
  • Efficiency and Efficacy: Interactive wound dressings offer healthcare providers a comprehensive toolkit for wound management, streamlining clinical workflows, and facilitating evidence-based decision-making. By enabling early detection of complications and timely interventions, these dressings contribute to improved clinical outcomes and reduced healthcare costs.

As the global interactive wound dressing market continues to evolve, stakeholders across the healthcare ecosystem are encouraged to embrace innovation, collaboration, and patient-centric approaches to drive meaningful advancements in wound care management.

Elevated Market Interest: Delve into In-Depth Trends and Insights with Our Full Report!

Competitive Landscape:

In an ever-evolving market landscape, a cadre of key players continues to redefine industry standards by unleashing cutting-edge products worldwide. These trailblazing companies, driven by a commitment to meeting consumer demands, are revolutionizing market expansion through a fusion of advanced technologies, pioneering strategies, and substantial investments in research and development.

These industry leaders are not merely introducing products; they are pioneering the future. Their relentless pursuit of innovation, coupled with a strategic focus on mergers, acquisitions, collaborations, and partnerships, marks a paradigm shift in market strategies.

  • In June 2023, Baxter International Inc. introduced the Progressa+ Next Gen ICIJ Bed, an advanced care solution that meets the complex needs of patients. Critical care patients, including those who need specialized wound care, will benefit from this innovative bed.

Key Companies Profiled:

  • Coloplast A/S
  • Medline Industries, Inc
  • B. Braun Melsungen AG
  • Medtronic plc
  • Integra LifeSciences Holdings Corporation
  • Lohmann & Rauscher GmbH & Co. KG
  • Gentell, Inc.
  • DermaRite Industries, LLC
  • Advancis Medical Ltd.

Market Segmentation:

By Product Type:

  • Semi-Permeable Wound Dressing
    • Semi-permeable films dressing
    • Semi-permeable foams dressing
  • Hydrogel dressing

By Application:

  • Chronic Wounds
  • Acute Wounds

By End Use:

  • Hospitals
  • Outpatient Facilities
  • Home care
  • Research & Manufacturing

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Growing Public Awareness and Government Initiatives Driving the Helicobacter Pylori Non-Invasive Testing Market Growth at a 4.4% CAGR

The global helicobacter pylori non-invasive testing market is projected to register at a moderate-paced CAGR of 4.4% over the forecast period. The helicobacter pylori non-invasive testing market is currently valued at USD 650.50 Million in 2023. By 2033, demand for helicobacter pylori non-invasive testing is expected to reach a high of USD 1000.57 Million.

The growth of the helicobacter pylori non-invasive testing market is expected to be spurred by factors such as the increasing prevalence of Helicobacter pylori bacterial infection, increased governmental awareness about infection for accurate diagnosis, and the launch of new products and the approval of those products by the Food and Drug Administration. Although the demand for helicobacter pylori non-invasive testing has potential, it is unlikely to develop due to problems like a low detection rate, the absence of any outward symptoms, and stringent regulatory constraints. However, doctors have still advised patients to get treatment for H. Pylori infections as soon as feasible, despite the lack of evidence linking COVID-19 and the virus.

Market share for non-invasive testing for Helicobacter pylori (H. pylori) is highest in North America, while growth is quickest in Asia-Pacific. Due to rising rates of gastric cancer, duodenal ulcers, and gastric ulcers, as well as the improvement of healthcare infrastructure, the North American helicobacter pylori non-invasive testing market is anticipated to expand throughout the forecast period.

During the forecast period, the market for non-invasive tests for H. pylori is expected to grow at a rate greatest in Asia Pacific. China, India, and Japan are just a few of the countries in the region where the demand for helicobacter pylori non-invasive testing is anticipated to expand at a rapid rate in the future years. As the ageing population in Asia and the Pacific rises, along with the frequency of Helicobacter pylori (H. pylori) and gastric cancer cases, the market for non-invasive testing of H. pylori is projected to expand. That’s why there’s so much opportunity for development in the region throughout the predicted expansion period for helicobacter pylori non-invasive testing market players.

Key Takeaways:

  • Demand for helicobacter pylori (H. pylori) non-invasive tests is anticipated to be driven by the rise in non-invasive testing for H. pylori diagnosis and the lack of endoscopic facilities.
  • The non-invasive testing demand for helicobacter pylori (H. pylori) is expanding due to increasing government awareness of infection and the need for accurate diagnosis, rising demand for point-of-care testing equipment, and the widespread availability of diagnostics tests.
  • The helicobacter pylori (H. pylori) non-invasive testing demand is anticipated to grow as a result of factors such as the increasing prevalence of H. pylori infection, the introduction of new products, and the approval of these products by the Food and Drug Administration.
  • The global ageing population and the rising number of people with stomach ulcers are expected to fuel the growth of the helicobacter pylori non-invasive testing market.
  • The adoption of non-invasive testing for helicobacter pylori (H. pylori) is expected to grow during the projected period due to rising technical developments and an increase in innovations.
  • The demand for non-invasive tests to identify helicobacter pylori (H. pylori) is projected to face challenges such as a low detection rate, the fact that H. pylori infection often has no symptoms, and strict regulatory regulations.

Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report!

Competitive Landscape:

The global helicobacter pylori non-invasive testing market comprises of the following players: Meridian Bioscience, Inc., DiaSorin S.p.A, Alere, Sekiusi Diagnostics and Biomerica, Inc. Besides these, a host of other players have a significant market presence as well. These are Biohit Oyj, Exalenz Bioscience Ltd., Aalto Bio Reagents Ltd., Certest Biotec S.L. and CorisBioconcept SPRL.

Recent Developments:

The FDA cleared Meridian Bioscience, Inc. to market its novel Curian and Curian HpSA assays in March of 2020. The new analyzer and initial assay are critical components of their plan to maintain market dominance in the testing of gastrointestinal diseases.

Thermo Fischer Scientific, a world-renowned provider of clinical research services to the biopharma and biotech industries, announced in December 2021 that it is expected to acquire PPD, Inc. for USD 17.4 billion.

Key Segments in the Helicobacter Pylori Non-Invasive Testing Market:

By Non-invasive Test Type:

  • Serology Test
  • Stool Antigen Test
  • Urea Breath Test

By Test Type:

  • Laboratory-based Tests
  • Point-of-Care Tests

By End-user:

  • Hospitals
  • Diagnostic Labs
  • Clinics

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA (Middle East and Africa)
  • Europe

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Severe Hypertriglyceridemia Treatment Market Poised for Significant Growth, Projected to Reach USD 2,675.37 Million by 2033: FMI Study

The global severe hypertriglyceridemia treatment market is experiencing robust growth, with a market value of USD 702.95 million in 2023 and an impressive forecasted growth to USD 2,675.37 million by 2033. This growth trajectory represents a compound annual growth rate (CAGR) of 14.3% from 2023 to 2033. The market’s expansion can be attributed to the rising prevalence of SHTG, coupled with ongoing technological advancements in the development of effective treatments.

Severe hypertriglyceridemia, a condition characterized by extremely high levels of triglycerides in the blood, significantly increases the risk of cardiovascular disease, pancreatitis, and other serious health complications. As the global incidence of SHTG continues to rise, the demand for effective treatments has surged. The market registered a CAGR of 8% in the historical period from 2018 to 2022, signaling a steady increase in the adoption of advanced therapies.

Technological innovations and advancements in the formulation of medications for severe hypertriglyceridemia are further driving market growth. New drug discoveries, particularly those focused on targeted therapies and personalized medicine, are expected to play a key role in expanding treatment options and improving patient outcomes.

Key Market Drivers:

  • Increasing prevalence of severe hypertriglyceridemia globally.
  • Technological advancements in the manufacturing of medications for SHTG.
  • Growing awareness about the importance of early diagnosis and treatment.

As the market continues to evolve, pharmaceutical companies are investing heavily in research and development to bring new, more effective treatment options to market. This trend is expected to propel the market forward, as healthcare providers and patients alike seek advanced, targeted therapies to manage and treat severe hypertriglyceridemia more effectively.

The future of the SHTG treatment market appears promising, with the potential for groundbreaking innovations to shape the industry and improve the quality of life for those affected by this condition.

Key Takeaways from the Market Study

  • The global Severe hypertriglyceridemia (SHTG) treatment market is expected to grow with a 14.3% CAGR during 2023 to 2033.
  • Hospital pharmacies are expected to hold 40% of the market share in 2023 for Severe hypertriglyceridemia (SHTG) treatment market.
  • North America is expected to possess 45% market share for Severe hypertriglyceridemia (SHTG) treatment market in 2023.
  • Europe severe hypertriglyceridemia (SHTG) treatment market size is expected to possess 39% market share in 2023.

“As more innovative therapies and drugs are developed, the market for SHTG treatment is likely to become even more competitive, with companies vying for a larger share of the market.” states an FMI analyst

Enhanced Interest in Market Trends: Access In-Depth Analysis and Insights with Our Full Report!

Competitive Landscape

Key players in the severe hypertriglyceridemia (SHTG) treatment market are Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia and Pfizer Inc.

  • Arrowhead Pharmaceuticals Inc lead drug candidate for SHTG is ARO-APOC3, an RNA interference (RNAi) therapeutic agent designed to target and silence the production of apolipoprotein C-III (APOC3), a protein that plays a key role in regulating triglyceride levels in the blood. In preclinical studies, ARO-APOC3 has been shown to significantly reduce triglyceride levels in animal models of SHTG.
  • NorthSea Therapeutics B.V lead drug candidate is called MBOAT7, which is an enzyme that plays a key role in the production of phosphatidylinositol-5-phosphate (PI5P), a lipid that is involved in regulating lipid metabolism. In preclinical studies, MBOAT7 has been shown to reduce triglyceride levels in animal models of SHTG.

Key Segments Profiled in the Severe Hypertriglyceridemia (SHTG) Treatment Market Survey:

Drug Class:

  • Olezarsen
  • Pegozafermin
  • Epeleuton
  • Lomitapide

Drug Delivery Method:

  • Oral Route
  • Injectable Route

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Stuttering Therapeutics Market Poised for Significant Growth, Expected to Reach USD 159.41 Million by 2033: FMI Study

The global stuttering therapeutics market is witnessing remarkable growth, with an anticipated market value of USD 43 Million in 2023. This market is projected to expand at a compound annual growth rate (CAGR) of 14%, reaching a significant value of USD 159.41 Million by 2033.

Stuttering, a speech disorder that affects millions worldwide, is increasingly being addressed through innovative therapeutic solutions. The growing awareness of stuttering and advancements in speech therapy treatments are driving the surge in market demand. Between 2018 and 2022, the market saw a consistent CAGR of 11%, reflecting a steady increase in the adoption of various therapeutic approaches, including speech therapy, medication, and technological interventions.

Experts attribute the projected 14% CAGR from 2023 to 2033 to the increasing focus on improving the quality of life for individuals with stuttering. The market growth is further fueled by ongoing research and development efforts aimed at creating more effective, personalized therapies.

Advancements in technology are also driving the growth of the stuttering therapeutics market. Electronic fluency devices, smartphone apps, and other technologies are being developed to help manage the symptoms of stuttering. These technologies offer non-invasive, convenient, and cost-effective options for individuals with stuttering, and are gaining popularity in the market.

Moreover, increased awareness and advocacy for stuttering are also driving the growth of the stuttering therapeutics market. There has been a significant increase in awareness and advocacy for stuttering in recent years, which has helped reduce the stigma surrounding the disorder and increased access to diagnosis and treatment for individuals with the disorder.

Key Takeaways from the Market Study:

  • From 2018 to 2022, the Stuttering Therapeutics market grew at a CAGR of 11%.
  • The global Stuttering Therapeutics market is expected to grow with a 14% CAGR during 2023 to 2033.
  • As of 2033, the Stuttering Therapeutics Market is expected to reach USD 159.41 Million.
  • According to the FMI analysis, the hospitals segment accounts for the largest market share.
  • North America is expected to possess 40% market share for the Stuttering Therapeutics market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Stuttering Therapeutics.” says an FMI analyst

Demand for Market Analysis: Our Comprehensive Report Offers Detailed Trends and Insights!

Market Competition:

Key players in the market include companies such as Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc.,  Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc. along with healthcare providers and technology companies among other global players.

  • In October 2022, Vivera announced that the US Patent and Trademark Office (USPTO) has granted a US patent allowance for the Company’s method and device for evaluating and providing feedback on Speech Fluency. Stuttering, a speech disorder that causes disfluencies in speech, affects 70 million individuals across the globe. Although there are treatments available, it can be challenging for clinicians to assess stuttering accurately, as its severity may fluctuate over time and in different situations.
  • Recognizing the need for a more precise evaluation of patient speech disfluencies in real-world settings, Vivera developed a stuttering severity assessment device. This innovative device allows for continuous monitoring of a patient’s stuttering, enabling a more accurate assessment and providing feedback to the patient in real-time. By gathering personalized patient data, clinicians can monitor the therapeutic effects of treatment and adjust therapy accordingly.

Key Segments Profiled in the Stuttering Therapeutics Industry Survey:

Treatment:

  • Speech therapy
  • Stuttering Devices
  • Cognitive behavioural therapy
  • Parent-child interaction
  • Drug therapy

Type:

  • Developmental stuttering
  • Neurogenic stuttering

End User:

  • Hospitals
  • Specialty Clinics
  • Homecare

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Radiotherapy Induced Oral Mucositis Treatment Market Poised for Growth, Expected to Reach USD 1,626.0 Million by 2034

The radiotherapy induced oral mucositis treatment market is likely to be USD 1,119.8 million in 2024. The adoption of radiotherapy induced oral mucositis treatment is predicted to expand at a CAGR of 3.8% through 2034. The industry is anticipated to cross USD 1,626.0 million by 2034.

The rising incidence of cancer, particularly head and neck cancers, is a primary driver for the radiotherapy induced oral mucositis treatment industry. As radiotherapy remains a cornerstone in cancer treatment, the demand for effective mucositis management solutions is escalating. Additionally, advancements in radiotherapy techniques and technologies have increased treatment efficacy and heightened the risk of oral mucositis, further propelling the need for innovative treatment options. Moreover, growing awareness among healthcare professionals and patients about the debilitating effects of oral mucositis has spurred research and development efforts to address this unmet medical need.

The radiotherapy induced oral mucositis treatment industry faces several restraints. Limited understanding of the underlying mechanisms of mucositis development poses challenges in developing targeted therapies. Additionally, the high cost of treatment options and reimbursement issues may hinder access to advanced therapies for certain patient populations. Furthermore, variability in treatment response and the lack of standardized guidelines for mucositis management contribute to treatment uncertainties and suboptimal outcomes.

The integration of complementary therapies, including acupuncture and herbal remedies, into standard mucositis management regimens holds promise for symptom relief and enhanced quality of life. Moreover, collaborative efforts between pharmaceutical companies, healthcare institutions, and research organizations can accelerate the development of novel therapeutic agents and targeted interventions for mucositis prevention and treatment.

Recent trends in the radiotherapy induced oral mucositis treatment industry focus on personalized medicine approaches and precision oncology strategies. Tailored treatment regimens based on patient-specific factors, such as genetic variations and treatment response biomarkers, are gaining traction in mucositis management. Additionally, the integration of advanced technologies, such as 3D printing and telemedicine, facilitates customized oral mucositis care delivery and remote patient monitoring. Furthermore, there is growing interest in exploring the potential of immunotherapy agents and regenerative medicine therapies in mitigating mucositis severity and promoting tissue healing post-radiotherapy.

“The radiotherapy induced oral mucositis treatment industry presents numerous opportunities for growth and innovation. Advancements in supportive care approaches, such as oral care protocols and nutritional interventions, offer avenues for improving patient outcomes and reducing treatment-related complications.” Says a Lead Analyst at FMI.

Key Takeaways from the Market Study:

  • The antibiotics segment holds dominance in 2024, with a market share of 36.20%, driven by the increasing prevalence of antibiotic-resistant infections.
  • Hospital pharmacy records high demand for radiotherapy induced oral mucositis treatment in 2024, commanding a market share of 38.10% due to hospitals being primary centers for cancer treatment.
  • Radiotherapy induced oral mucositis treatment industry in the United Kingdom projects a rise at a CAGR of 3.40% through 2034, propelled by evolving healthcare infrastructure and increased accessibility to advanced radiotherapy treatments.
  • Radiotherapy induced oral mucositis treatment industry in China is expected to witness expansion at a CAGR of 6.70% through 2034, driven by rapidly expanding healthcare infrastructure and investments in oncology services.
  • Radiotherapy induced oral mucositis treatment industry in India is anticipated to rise at a 7.20% CAGR through 2034, owing to the growing demand for radiotherapy services and supportive care products.

Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!

Competitive Landscape:

The radiotherapy induced oral mucositis treatment industry is dynamic, with established pharmaceutical giants, specialized players, and innovative startups vying for market share. Leading companies like Pfizer, Amgen, Merck & Co., and EpicentRx leverage their extensive resources and marketed products to maintain a strong presence. Meanwhile, specialty players like Galera Therapeutics and OraVerse bring targeted expertise with focused solutions like Neupogen and MuGard. The industry is further characterized by emerging players like Oncodesign and Cellectis, who are pushing boundaries with KL12 peptide-based treatments and personalized CAR-T cell therapies, respectively.

Competition hinges on several key factors. Product differentiation through mechanisms of action, delivery methods, and targeted patient populations is crucial. Companies are actively exploring novel technologies like gene therapy, stem cells, and nanomedicine to gain an edge. Strategic partnerships between players across the spectrum, from pharmaceutical giants to research institutions and patient advocacy groups, are becoming increasingly common. However, navigating complex regulatory hurdles can pose a challenge, especially for smaller players.

Looking ahead, the industry is poised for further transformation. Precision medicine, with its focus on tailoring treatments to individual patients, is gaining momentum. Combination therapies that merge different modalities are expected to improve efficacy. Additionally, a growing emphasis on patient-centric solutions that enhance comfort and well-being is driving innovation. The integration of digital health tools like mobile apps and telemedicine holds promise for improved patient care and engagement. As the competition intensifies with continuous advancements, companies demonstrating a commitment to scientific progress, patient-centricity, and strategic collaboration are likely to emerge as victors in this evolving market.

Recent Developments:

  • Galera Therapeutics filed a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for avasopasem manganese (avasopasem) to treat severe oral mucositis (SOM) in patients with head and neck cancer (HNC) after standard-of-care radiation. However, the FDA sent the business a Complete Response Letter (CRL), suggesting that the NDA cannot be authorized in its current form.
  • EpicentRx is developing RRx-001, a new immunotherapy that may make tumors more susceptible to radiation and chemotherapy. The FDA awarded RRx-001 Orphan Drug Designation for the prevention of oral mucositis in HNC patients.
  • Pfizer introduced Zirabev, a biosimilar of bevacizumab, in the United States to treat a variety of solid tumors. In a randomized experiment, Zirabev was shown to lessen the severity of oral mucositis in individuals undergoing radiation for HNC.
  • Merck & Co. collaborated with Eisai to develop and market eribulin, a microtubule inhibitor that can treat a variety of cancers. Phase 2 research found that eribulin reduced the incidence and severity of oral mucositis in breast cancer patients undergoing radiation.

Key Companies in the Market:

  • Galera Therapeutics
  • OraVerse
  • EpicentRx
  • Biocon
  • Oncodesign
  • Cellectis
  • Pfizer
  • Amgen
  • Merck & Co.

Key Segments:

By Drug Class:

  • Antibiotics
  • Antifungal
  • Anti-Inflammatory
  • Anti-Neoplastic

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End User:

  • Hospitals
  • Oncology Centres
  • Research Institutes
  • Dental Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Secondary Myelofibrosis Therapeutics Market Set for Robust Growth, Projected to Reach USD 2.74 Billion by 2033

The global secondary myelofibrosis therapeutics market is poised for significant growth, with an estimated market value of USD 2.74 billion by 2033, marking a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period of 2023 to 2033. This promising market growth comes on the heels of a market value of USD 1.49 billion in 2023.

The expansion of the secondary myelofibrosis therapeutics market is primarily driven by the increasing incidence of the disease, rising investments in research and development, and the emergence of innovative therapeutic alternatives. Over the past few years, the market experienced a steady CAGR of 3.3% from 2018 to 2022, as new therapies and advancements in treatment options began to gain traction.

Secondary myelofibrosis, a form of bone marrow fibrosis often stemming from other underlying conditions such as chronic inflammatory diseases or cancers, remains a significant global health concern. With the ongoing research into novel treatments, including targeted therapies and advanced biologics, the market is expected to witness a surge in the availability of effective therapeutic solutions.

The surge in market value can also be attributed to growing awareness about the disease, improved diagnostic capabilities, and the increasing need for comprehensive treatment options to manage this complex condition. As pharmaceutical companies invest in the development of advanced drugs and therapies, the global secondary myelofibrosis therapeutics market is well-positioned for continued growth.

Key Factors Driving Market Growth:

  1. Increase in Disease Incidence: Rising cases of secondary myelofibrosis, especially among patients with chronic diseases, continue to fuel the demand for targeted therapies.
  2. R&D Investment: Significant investments in research and development are contributing to the emergence of advanced therapies, including JAK inhibitors and other novel drug classes.
  3. Innovation in Treatment Options: The development of alternative treatment strategies and new drug formulations offers hope for more effective and personalized treatment solutions.

As the global healthcare landscape evolves, the secondary myelofibrosis therapeutics market is set to play a crucial role in addressing the growing demand for effective treatments for this complex condition.

Key Takeaways from the Market Study:

  • The Secondary myelofibrosis therapeutics market is expected to grow at a value of 6.3% CAGR in the forecast period 203 to 2033.
  • By distribution channel, hospital pharmacies are expected to possess 40% market share for SMF therapeutics market in 2023.
  • North America is expected to possess 42% market share for Secondary myelofibrosis therapeutics market in 2023.
  • Europe Secondary myelofibrosis therapeutics market size is expected to possess 40% market share in 2023.

“In addition to new drug development, there has also been a focus on improving the use of existing treatments for myelofibrosis, including secondary myelofibrosis. This, in turn, is driving the growth of the market.” states an FMI analyst

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Competitive Landscape:

Key players in the secondary myelofibrosis therapeutics market are CTI BioPharma Corp, Incyte Corporation, Bristol-Myers Squibb Company, Amneal Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., Actuate Therapeutics Inc., Imago BioSciences, Galecto, Inc.

  • CTI BioPharma has also conducted preclinical research on a number of other therapeutic candidates for secondary myelofibrosis, including compounds that target the TGF-β signaling pathway and the HIF-2α pathway.
  • Incyte Corporation has contributed to the development of ruxolitinib, a JAK1/JAK2 inhibitor that has been approved for the treatment of primary and secondary myelofibrosis, as well as conducting preclinical research on other therapeutic candidates for secondary myelofibrosis.

Key Segments Profiled in the Secondary Myelofibrosis Therapeutics Industry Survey:

Treatment:

  • Targeted therapy
  • Chemotherapy
  • Radiation therapy

Diagnosis:

  • Physical exam
  • Blood tests
  • Imaging tests
  • Bone marrow examination

Drug Class:

  • Ruxolitinib
  • Fedratinib
  • Pomalidomide

Distribution Channel:

  • Hospital pharmacies
  • Retail and specialty pharmacies
  • Online pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Neovascular Age-Related Macular Degeneration Treatment Market Set for Significant Growth: Projected to Reach USD 4.89 Billion by 2033

According to the latest market research report by Future Market Insights, the global neovascular age-related macular degeneration treatment market is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) of 5% from 2023 to 2033. Valued at USD 3 billion in 2023, the market is anticipated to reach an impressive USD 4.89 billion by the end of the forecast period.

Neovascular age-related macular degeneration is a prevalent and serious condition, primarily affecting individuals aged 50 and above. It stands as a leading cause of vision loss within this demographic, significantly impacting global eye health. The condition is characterized by the abnormal growth of blood vessels beneath the retina, resulting in fluid and blood leakage. This process damages the macula, the central region of the retina responsible for sharp and detailed vision, leading to severe visual impairment.

North America and Europe are the largest markets for nAMD treatment, with the United States, Germany, and the United Kingdom being the major contributors. The strong healthcare infrastructure, increasing patient awareness, and availability of advanced treatment options are the key factors driving growth in these regions. However, the report notes that the Asia Pacific region is expected to experience significant growth in the coming years, driven by increasing prevalence of nAMD, expanding healthcare infrastructure, and introduction of new treatments.

Key Takeaways from the Market Study:

  • From 2018 to 2022, the neovascular age-related macular degeneration treatment market grew at a CAGR of 3.5%.
  • The global neovascular age-related macular degeneration treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
  • As of 2033, the Neovascular Age-related Macular Degeneration Treatment Market is expected to reach USD 4.89 Billion.
  • According to the FMI analysis, the Wet AMD segment accounts for the largest market share.
  • North America is expected to possess 40% market share for the Neovascular Age-related Macular Degeneration Treatment market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Neovascular Age-related Macular Degeneration Treatment.” says an FMI analyst

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Market Competition:

Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.

  • Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant was granted FDA approval on October 22, 2021. This approval is for the treatment of wet or neovascular age-related macular degeneration (AMD) in individuals who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a leading cause of blindness in people aged 60 and older and affects approximately 1.1 million people in the United States.

Key Segments Profiled in the Neovascular Age-related Macular Degeneration Treatment Industry Survey:

Drug Type:

  • Ranibizumab
  • Aflibercept
  • Bevacizumab
  • Brolucizumab
  • Faricimab

Disease Type:

  • Dry AMD
  • Wet AMD

Age Group:

  • Less than 60
  • Between 60 to 80
  • More than 80

Gender:

  • Male
  • Female

Stage of Disease:

  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD

Distribution Channel:

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Lupus Nephritis Treatment Market to Reach USD 5.67 Billion by 2033, Driven by Rising Incidence and Advancements in Treatment: FMI Study

The global lupus nephritis treatment market, valued at USD 2 billion in 2023, is set to experience significant growth, reaching an estimated market value of USD 5.67 billion by 2033. This expansion reflects a compound annual growth rate (CAGR) of 11% during the forecast period from 2023 to 2033.

Several factors contribute to this upward trajectory, including the rising incidence of lupus nephritis, an autoimmune disease that primarily affects the kidneys, as well as increased awareness surrounding the condition. The growing recognition of lupus nephritis has led to a surge in demand for treatments that can effectively manage and alleviate the symptoms of the disease. Furthermore, the market is benefiting from the emergence of novel therapies that offer innovative treatment options, improving patient outcomes and driving the demand for advanced care.

The market has already demonstrated a promising growth rate of 6.5% CAGR in the historical period from 2018 to 2022, indicating a solid foundation for continued expansion. With a growing number of treatment options and greater understanding of the disease, the lupus nephritis treatment market is poised for substantial development over the next decade.

As the healthcare landscape continues to evolve, companies within the lupus nephritis treatment sector are encouraged to innovate and collaborate, ensuring the delivery of effective and groundbreaking therapies to address the needs of patients worldwide.

Key Takeaways from the Market Study:

  • The Lupus nephritis treatment market is expected to grow at a value of 11% CAGR in the foreast period 2023 to 2033
  • Hospital pharmacies are expected to hold 45% of the market share in 2023 for Lupus nephritis treatment market.
  • North America is expected to possess 44% market share for Lupus nephritis treatment market in 2023.
  • Europe Lupus nephritis treatment market size is expected to possess 40% market share in 2023.

“Researchers and pharmaceutical companies are continuing to develop new and innovative therapies for lupus nephritis. This, in turn, is contributing to growth of the market.” states an FMI analyst

Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report!

Competitive Landscape:

Key players in the lupus nephritis treatment are Roche, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, AstraZeneca, Aurinia Pharmaceuticals Inc., Johnson & Johnson Private Limited, Bayer AG, Sanofi, Sun Pharmaceutical Industries Ltd and Abbott

  • BMS has sponsored several clinical trials focused on developing treatments for lupus nephritis. For example, the company is currently sponsoring a Phase III clinical trial to investigate the efficacy and safety of abatacept in combination with mycophenolate mofetil (MMF) in patients with lupus nephritis.
  • In 2021, Eli Lilly announced positive results from a Phase 3 clinical trial of Olumiant in patients with lupus nephritis. The trial showed that Olumiant, in combination with standard-of-care treatment, significantly improved kidney function compared to standard-of-care treatment alone. Based on these results, Eli Lilly has submitted an application for regulatory approval of Olumiant as a treatment for lupus nephritis.

Key Segments Profiled in the Lupus Nephritis Treatment Market Survey:

Drug Class:

  • Corticosteroids
  • Immunosuppressive
    • Azathioprine
    • Cyclophosphamide
    • Mycophenolate
  • Belimumab

Route of Administration:

  • Oral
  • Parenteral

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube